Antibiotics are fundamental to modern medicine, essential for treating everything from routine skin infections to strep throat, and for protecting vulnerable patients receiving chemotherapy or being treated in intensive care units. But the proliferation of antibiotic-resistant bacteria—a result of decades of overuse in animal agriculture and human medicine combined with a lack of new drug development and innovation—has placed humanity on the precipice of what public health leaders call a “post-antibiotic” world in which even the most simple surgical procedure could have deadly consequences.
Although antibiotic resistance is not a new problem, its scope now constitutes a major threat to human health. According to the Centers for Disease Control and Prevention, at least 2 million Americans fall sick every year with antibiotic-resistant infections—and 23,000 die.
Medical and public health experts agree that addressing antibiotic resistance requires measures that will ensure both the prudent use of existing drugs and a robust pipeline of new drugs. Pew's antibiotic resistance project supports policies that would:
- Spur the creation of new antibiotics by removing the regulatory, economic, and scientific obstacles that impede antibiotic discovery and development.
- Establish stewardship programs to ensure that antibiotics are prescribed only when necessary in human health care settings.
- End the overuse of antibiotics in food animals.
The Obama administration today released an implementation plan for its Combating Antibiotic-Resistant Bacteria (CARB) strategy, which it announced in September. Allan Coukell, senior director for health programs at The Pew Charitable Trusts, provided a statement. Read More
Despite the pressing need for new drugs, few of the antibiotics currently in development target CRE or other difficult-to-treat bacteria. Read More
Surveys of the animal production industry by the U.S. Department of Agriculture demonstrate that industrial-scale facilities frequently administer antibiotics to animals at low doses for nontherapeutic purposes—a practice that the medical and public health communities document as a significant factor in human antibiotic resistance. In fact, the U.S. Food and Drug Administration... Read More